LOGIN  |  REGISTER
Terns Pharmaceuticals
Chimerix

Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024

October 09, 2024 | Last Trade: US$6.89 0.10 1.47

LAVAL, QC / ACCESSWIRE / October 9, 2024 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) will release third quarter 2024 financial results after market close on Wednesday, October 30, 2024. Bausch Health will host a conference call and live webcast at 5:00 p.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.

Conference Call Details

Date:

Wednesday, October 30, 2024

Time:

5:00 p.m. U.S. EST

Webcast:

https://ir.bauschhealth.com/events-and-presentations

A replay of the conference call will be available on the investor relations website.

To participate in the live Q&A session, please register using this link to receive an email confirming your registration with further details.

About Bausch Health

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, medical aesthetic devices, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information, visit www.bauschhealth.com and connect with us on LinkedIn.

Investor Contact:
Garen Sarafian
This email address is being protected from spambots. You need JavaScript enabled to view it.
(877) 281-6642 (toll-free)

 

Media Contact:
Katie Savastano
This email address is being protected from spambots. You need JavaScript enabled to view it.
(908) 541-3785

Astria Therapeutics

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page